Thanks for that clarification, and for the welcome. Glad to be here.
So now my question is, why would a SOC be limited to the single (coformulation) drug as opposed to the 2 drugs that make up that coformulation? We often see that inpatients in a hospital who usually take a coformulation drug end up on the separate components while in hospital, simply because they are the cheaper option.
If the answer is that the coformulation is potentially a lot safer because of the coformulation itself, and that this cannot be achieved by taking the 2 things together as separate drugs, then I understand the argument. But if it is simply a matter of a certain drug combination, then coformulation is not necessarily going to be the SOC and therefore a medico could not be held to only prescribe in that manner for fear of deviating from the SOC.
I am assuming in advance that it is the potential of the coformulation itself that is the winner here, and at present the 2 drugs are the only versions of themselves and therefore ripe to get into bed together.
- Forums
- ASX - By Stock
- Ann: Expanded Heart Protection Discovery for Zantrene
Thanks for that clarification, and for the welcome. Glad to be...
-
- There are more pages in this discussion • 206 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M |
Open | High | Low | Value | Volume |
$1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3105 | $1.94 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.95 | 7574 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3105 | 1.940 |
2 | 30000 | 1.900 |
1 | 4861 | 1.880 |
1 | 3000 | 1.850 |
1 | 30000 | 1.840 |
Price($) | Vol. | No. |
---|---|---|
1.950 | 7574 | 1 |
1.995 | 10037 | 1 |
2.000 | 8000 | 3 |
2.020 | 4000 | 1 |
2.040 | 2000 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |